Intrexon Corp (XON) is Initiated by JMP Securities to Mkt Outperform

Intrexon Corp (XON) was Initiated by JMP Securities to “Mkt Outperform”. JMP Securities advised their investors in a research report released on May 3, 2016.

Many Wall Street Analysts have commented on Intrexon Corp. Shares were Reiterated by Stifel on Mar 1, 2016 to “Buy” and Lowered the Price Target to $ 57 from a previous price target of $69 .Company shares were Reiterated by Mizuho on Mar 1, 2016 to “Neutral”, Firm has raised the Price Target to $ 29 from a previous price target of $28 .

On the company’s financial health, Intrexon Corp reported $-0.28 EPS for the quarter, missing the analyst consensus estimate by $ -0.06 based on the information available during the earnings call on Feb 29, 2016. Analyst had a consensus of $-0.22. The company had revenue of $41.50 million for the quarter, compared to analysts expectations of $41.81 million. The company’s revenue was up 33.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.18 EPS.

Intrexon Corp opened for trading at $26.57 and hit $27.73 on the upside on Monday, eventually ending the session at $27.55, with a gain of 3.07% or 0.82 points. The heightened volatility saw the trading volume jump to 22,87,326 shares. Company has a market cap of $3,217 M.

In a different news, on Dec 14, 2015, Randal J Kirk (CEO) purchased 124,475 shares at $29.84 per share price. According to the SEC, on Dec 4, 2015, Krish S Krishnan (Chief Operating Officer) sold 20,900 shares at $33.02 per share price. On Dec 4, 2015, Suma Krishnan (SVP–Product Development) sold 20,900 shares at $33.02 per share price, according to the Form-4 filing with the securities and exchange commission.

Intrexon Corporation is engaged in the field of synthetic biology. The Company designs builds and regulates gene programs which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount location and modification of biological molecules to control the function and output of living cells. The Company’s technologies include UltraVector RheoSwitch Therapeutic System Cell Systems Informatics Protein Engineering AttSite Recombinases LEAP (Laser Enabled Analysis and Processing) Antibody Discovery Neurospora & Agaricus Platforms Endometrial Regenerative Cells ActoBiotics Porcine Research Models and BeyondBio. The Company serves various markets including health food energy environment and consumer. The Company has five operating divisions: Human Therapeutics Synthetic Immunology Animal Sciences Agricultural Biotech and Industrial Products.

Intrexon Corp

Leave a Reply

Intrexon Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Intrexon Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.